Shares of Prime Medicine ( PRME 13.07%) are surging on Thursday. The gene-editing company's stock gained 10.5% as of 2 p.m.

These data are meaningful both for the company’s efforts in Wilson ... If you are looking for a deeply undervalued AI stock that is more promising than PRME but that trades at less than ...

Shares of Prime Medicine, Inc. PRME were up 11.85% after the company announced a strategic research collaboration and license agreement with biotech giant Bristol Myers Squibb BMY.

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Chardan Capital reaffirmed their buy rating on shares of Prime Medicine (NYSE:PRME – Free Report) in a research note released on Monday morning,Benzinga reports. The firm currently has a $15.00 target ...

Shares of NYSE:PRME opened at $2.60 on Tuesday. The company has a 50 day moving average of $2.90 and a 200 day moving average of $3.59. The stock has a market cap of $341.02 million, a P/E ratio ...

Market Capitalization Reflects the total market value of a company. Market Cap is calculated by multiplying the number of shares outstanding by the stock's price. For companies with multiple ...

This put 26.46% of the company's publicly available shares short. Short interest in Prime Medicine Corp (XNAS ... their positions without sending the stock sharply higher.

The Company is also pleased to provide a summary of its 2024 drill program highlights and other activities. Prime is focused on ... how these factors influence stock valuations.

The release of positive FiH data for PM359 in CGD could serve as a significant catalyst for Prime Medicine’s stock. Successful results would not only validate the company’s Prime Editing ...